ArticlePharmacotherapy2026
Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis.
Article in Pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis.Pharmacotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIntravenous push (IVP) administration of cefepime increases ease of preparation and limits the need for small volume parenterals. The data on IVP pharmacokinetic/pharmacodynamic (PK/PD) parameters are limited, but may be especially relevant in critically ill patients with altered PK/PD for time-dependent antibiotics like cefepime. The objective of this study was to characterize the PK profile and PD target attainment of IVP cefepime in critically ill patients with sepsis.
methodsIn this institutional review board-approved, prospective, noninterventional PK study, hospitalized adult patients receiving IVP cefepime were included if they had a central/midline catheter, intensive care unit (ICU) length of stay ≥ 48 h, creatinine clearance > 30 mL/min without renal replacement therapy, and diagnosis of sepsis. Blood samples were obtained at cefepime steady state immediately before and at 5, 15, 30, 60, 120, and 240 min after a dose. Serum concentrations of cefepime were measured using high-performance liquid chromatography with ultraviolet detection. Patient characteristics and outcomes were collected retrospectively from the electronic health record. The primary outcome was the PK profile of cefepime following IVP administration.
resultsPatients (n = 17) had a median age of 69 years, body mass index (BMI) of 29.9 kg/m
conclusionsIntravenous push cefepime in critically ill patients achieved systemic exposure comparable to traditional intermittent infusion but demonstrated substantial interpatient PK variability. These findings highlight the impact of critical illness on cefepime disposition and support further evaluation of personalized cefepime dosing for the ICU population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.